FDA raises safety issues concerning propoxyphene.
Aschenbrenner
Diane S
DS
Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D011431:Dextropropoxyphene / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D062787:Drug Overdose / Q000517:prevention & control; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans
D000701:Analgesics, Opioid; D065692:Cytochrome P-450 CYP3A Inhibitors; D004791:Enzyme Inhibitors; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D011431:Dextropropoxyphene